Abstracts Archive

The AITL cell-of-origin, a T-follicular helper cell (TFH), has a set of mutations also found in some PTCL-NOS; this similarity has led to a reclassification (WHO 5th edition), grouping AITL, PTCL-NOS w/TFH phenotype, and follicular-T-cell lymphoma together as nodal TFH lymphoma (nTFHL). Duvelisib i...

The clinical, pathologic, and genetic features in MF and SS are highly heterogeneous with significant inter- and intra-patient variability thus requiring a highly personalized approach to management.  The current clinical staging system is inadequate in enabling clinicians to provide optimal risk-s...

Introduction: Cutaneous T cell lymphomas (CTCL) are rare forms of non Hodgkin lymphoma. CTCL disease stage is a key indicator of patient outcomes, and presence of peripheral blood involvement is a particularly important predictor of survival rates and disease progression. Since the characteristics o...

Introduction:Total skin electron therapy (TSET) is an effective treatment for cutaneous T-cell lymphomas (CTCL). However, the nuances of patient setup and treatment delivery present challenges for treatment verification. Objectives: To report on the utility of Cherenkov imaging, a novel mo...

Background:Although many patients with Large granular lymphocytic leukemia present with cytopenias at diagnosis, the necessity for targeted treatment is not universally indicated. The diagnostic landscape is complicated by the coexistence of factors including autoimmune conditions, clonal hematopoie...

Introduction: PC4SMPTCL is a rare subtype of cutaneous T-cell lymphoma with generally indolent behavior but variable clinical outcomes. While most cases exhibit a favorable prognosis, some patients experience disease progression, recurrence, or systemic involvement. Objectives: This study ...

Introduction: Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma, and the vast majority of cases are CD4+, where CD4+ lymphocytes outnumber CD8+ lymphocytes in affected tissue. The converse, CD8+ MF, is rare, with little known regarding how it differs from CD4+ MF. O...

Introduction:A patient with mycosis fungoides (MF) harboring a PCM1-JAK2 fusion experienced a durable response to ruxolitinib before developing resistance. Here, we detail the case and the molecular profiling of her tumors before and after ruxolitinib resistance.Methods:Mutational profiling was perf...

Introduction: Outcomes of majority of patients with advanced TCL are poor. The value of ctDNA as a prognostic marker of chemosensitivity and disease-free survival has been validated in aggressive B-cell lymphomas but its role remain unclear in TCL. Objective: To determine the feasibility of lon...

Introduction: Mature T- and NK-cell neoplasms (MTNKN) exhibit a significantly higher incidence in LATAM compared to Western Europe and North America. This disparity is partly attributed to a high prevalence of EBV and HTLV-1. Despite the elevated burden of MTNKN in these regions, comprehensive data ...

Introduction: ENKTL is an aggressive disease and patients with early non upper aero digestive tract (NUAT) or advanced stage disease often exhibit an aggressive clinical course. Mitoxantrone hydrochloride liposome has demonstrated efficacy in relapsed/refractory ENKTL in a phase II clinical trial. M...

ENKTL occurs predominantly in Asian populations and data is limited in North America. We performed a retrospective analysis to define treatment patterns and outcomes for North American ENKTL patients to assess the impact of asparaginase (AS...

Introduction:Mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) are common subtypes of CTCLs. ALCANZA trial showed brentuximab vedotin (BV) significantly improved ORR4 (objective response rate lasting ≥ 4 months) in CD30+ CTCLs patients compared with conventional ...

Introduction: LGLL is a rare lymphoproliferative disorder where somatic STAT3 mutation is common. The clinical characteristics and therapeutic response of LGLL−associated PRCA are largely unclear. Methods: STAT3 mutation detection was conducted in 81 LGLL−associated PRCA patients registered in t...

IntroductionMonomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is an aggressive lymphoma with occasional multifocality. Methods, ObjectivesWe retrospectively investigated the clinicopathologic characteristics of MEITL patients, with a focus on multifocality and p...

Introduction: T-LGL is a rare chronic lymphoproliferative disorder. It is often associated with a spectrum of clinical manifestations, resulting in significant clinical course and outcome heterogeneity. Objectives: This study aims to evaluate the clinicopathologic factors impacting T-LGL survival. M...

Introduction: T-large granular lymphocyte leukemia (T-LGLL) accounts for an important portion of secondary pure red cell aplasia (PRCA) patients. For CsA-resistant or relapsed patients, outcomes of sequential regimen consisting of cyclophosphamide combined with prednisone (CP) have been less reporte...

IntroductionPeripheral T-cell lymphomas (PTCL) are rare, heterogeneous, aggressive lymphomas. Current monotherapies have overall response rates (ORR) of <30% (except brentuximab vedotin for CD30+ ALCL). Duvelisib is an oral inhibitor of phosphatidylinositol 3-kinase-δ and -γ isoforms. PRIMO (NC...

Introduction:Mycosis Fungoides/Sézary Syndrome (MF/SS) are primary cutaneous T-cell lymphomas (CTCLs) characterized by cutaneous involvement by clonal CD4+ mature T cells. Many patients with advanced disease develop circulating tumor cells, and even low levels of blood involvement (<250 clonal t...

T-prolymphocytic leukemia (TPLL) is a rare, poor-prognostic, mature T-cell malignancy associated with an aggressive clinical course in the context of limited therapeutic options. Despite exponentially rising tumor burden, mainly in blood, bone marrow, and spleen, we discovered that many TPLL patient...

PTX-100 is a potent small molecule that targets GGTase1, inhibiting a crucial post-translational modification required for the oncogenic activity of RAS family proteins. The clinical potential of PTX-100 was first highlighted in two Phase 1 dose-finding trials: one in solid tumors (TG-GTI-001) and o...

Introduction: We engineered a PEGylated polymer nanoparticle (PNP) encapsulating the potent Class 1 HDAC inhibitor romidepsin and demonstrated its superior tolerability and efficacy compared to free romidepsin T-cell lymphoma models. The PNP was optimized with focus on physicochemical propertie...

A 69-year-old male presented with a 5-month history of pruritus and lymphocytosis. The exam revealed a 5 cm purple nodule on the left axilla, and pink papules and plaques on the back. Punch biopsies showed dense dermal infiltrates of atypical CD4+, PD1+, and GATA3+ T-cells with intraepidermal and fo...

Introduction:While HBV-associated DLBCL exhibits distinct clinical characteristics and outcomes, the association between HBV infection and mature T-cell and NK-cell lymphomas (TNKLs) and its impact on outcomes remain unexplored. Objectives:To define the impact of HBV infection (HBV+, defined as...

Introduction: Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) is a rare subtype of primary cutaneous T-cell lymphoma. Due to its rarity and clinical overlap with other CD30-positive lymphoproliferative disorders, the prognostic impact of various clinical and pathological factors is not ful...

Background: Frontline therapies in Mature T/NK-cell Lymphomas need optimization given the high incidence of primary refractoriness and relapse. In retrospective studies, adding etoposide to CHOP (CHOEP) improved PFS in younger and ALK+ ALCL patients, whereas BVCHP improved PFS and OS over CHOP ...

We reviewed 1,143 lymphoid neoplasm of pediatrics, adolescents, and young adults (PAYA), and analyzed the distribution of T/NK-cell neoplasms according to the 5th WHO classification. Of these 1,143 lymphoid neoplasms, 937 (82%) were non-Hodgkin lymphomas, including 685 (73.1%) B-cell and 252 (26.9%)...

Introduction:This abstract focuses on the activity of BI-1808, a monoclonal antibody targeting TNFR2, in patients with cutaneous T-cell lymphoma (CTCL). TNFR2 overexpression on malignant CD4+CD26- T-cells points to its possible implication in the pathogenesis of CTCL. BI-1808 inhibits the interactio...

Aim:Cutaneous T-cell lymphomas (CTCL) are typically incurable, associated with significant symptom burden over prolonged time.  Unique hurdles to diagnosis arise from disease rarity, overlapping morphological appearances and low biopsy-rates. This epidemiological study investigated th...

Introduction:T-cell lymphoma (TCL) derived from CAR-T cells is a rare event (2 cases reported) in multiple myeloma (MM) patients receiving ciltacabtagene autoleucel (cilta-cel). Here, we present an enterotropic CAR+TCL post-cilta-cel, with unique genomic features.Methods: The presence of CAR+ c...